Table 5

Pathological complete response relative to molecular subtypes of tumor with empirical cut-offs for Ki67

Tumor classification (+: yes/-: no)

Tumor response


ER/PR

HER2

Ki67

Neoadjuvant

All

pCR no

pCR yes


trastuzumab

N

%

n

%

n

%

P


Hormone receptor-positive

+

-

≥ 38%

NA

53

100

43

81.1

10

18.9

< 0.0001

+

-

< 38%

NA

263

100

255

97.0

8

3.0

+ or -

+

≥ 18%

+ or -

80

100

43

53.7

37

46.3

0.02

HER2-positive

+ or -

+

< 18%

+ or -

22

100

18

81.8

4

18.2

+ or -

+

+ or -

+

50

100

24

48.0

26

52.0

0.03

+ or -

+

+ or -

-

52

100

37

71.2

15

28.8

Triple negative

-

-

≥ 35%

NA

105

100

48

45.7

57

54.3

< 0.01

-

-

< 35%

NA

24

100

20

83.3

4

16.7


All

+ or -

+ or -

+ or -

+ or -

547

100

427

78.1

120

21.9


ER, estrogen receptor; HER2, HER2/neu receptor; NA, not applicable; PR, progesterone receptor.

Fasching et al. BMC Cancer 2011 11:486   doi:10.1186/1471-2407-11-486

Open Data